Shield seeks US partner after PDUFA confirmed

13 December 2018

Specialty UK pharma company Shield Therapeutics (LSE: STX) will know the fate of its New Drug Application (NDA) for its iron deficiency drug Feraccru (ferric maltol) by July 27, 2019.

The Prescription Drug User Fee Act date for completion of the review has been announced by the Food and Drug Administration, as Shield seeks to gain access to the US market, where the company currently retains all rights to the drug but is looking for a commercial partner.

Feraccru has already been approved in Europe for iron deficiency in adults, and Netherlands-headquartered company Norgine has in-licensed rights to the drug there, and has started sales and marketing activities.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK